ERBB2 and breast carcinoma: HER2 positivity in breast cancer can promote T-cell and monocyte recruitment in trastuzumab-sensitive tumours [16], whereas the “immune-cold” phenotype in HER2-positive EGA, with lower CD8+ T-cell and NK cell infiltration compared with HER2-negative tumours, contrasts with this.